{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T08:12:36Z","timestamp":1698394356235},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00108-023-01579-x","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T14:03:59Z","timestamp":1696860239000},"page":"1130-1132","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bariatrische Chirurgie bei nichtalkoholischer Steatohepatitis","Bariatric surgery in nonalcoholic steatohepatitis"],"prefix":"10.1007","volume":"64","author":[{"given":"Elke","family":"Roeb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirka","family":"Nitschmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"key":"1579_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","volume":"129","author":"LA Adams","year":"2005","unstructured":"Adams\u00a0LA, Lymp\u00a0JF, Sauver\u00a0StJ et al (2005) The natural history of nonalcoholic fatty liver disease: a\u00a0population-based cohort study. Gastroenterology 129:113\u2013121","journal-title":"Gastroenterology"},{"key":"1579_CR2","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba\u00a0R, Abdelmalek\u00a0MF, Armstrong\u00a0MJ et al (2023) Semaglutide 2\u00b74\u202fmg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a\u00a0randomised, placebo-controlled phase\u00a02\u00a0trial. Lancet Gastroenterol Hepatol 8:511\u2013522","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1579_CR3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/hep.32358","volume":"76","author":"R Pais","year":"2022","unstructured":"Pais\u00a0R, Aron-Wisnewsky\u00a0J, Bedossa\u00a0P et al (2022) Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery. Hepatology 76:456\u2013468","journal-title":"Hepatology"},{"key":"1579_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520","author":"ME Rinella","year":"2023","unstructured":"Rinella\u00a0ME, Lazarus\u00a0JV, Ratziu\u00a0V et al (2023) A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J\u00a0Hepatol. https:\/\/doi.org\/10.1097\/HEP.0000000000000520","journal-title":"J Hepatol"},{"key":"1579_CR5","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1055\/a-1880-2283","volume":"60","author":"E Roeb","year":"2022","unstructured":"Roeb\u00a0E, Canbay\u00a0A, Bantel\u00a0H et\u00a0al (2022) Z\u00a0Gastroenterol 60:1346\u20131421","journal-title":"Z Gastroenterol"},{"key":"1579_CR6","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","volume":"401","author":"O Verrastro","year":"2023","unstructured":"Verrastro\u00a0O, Panunzi\u00a0S, Castagneto-Gissey\u00a0L et al (2023) Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a\u00a0multicentre, open-label, randomised trial. Lancet 401:1786\u20131797","journal-title":"Lancet"},{"key":"1579_CR7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez\u00a0E, Martinez-Perez\u00a0Y, Calzadilla-Bertot\u00a0L et al (2015) Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149:367\u2013378.e365 (quiz e314\u2013365)","journal-title":"Gastroenterology"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01579-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-023-01579-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01579-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T08:02:46Z","timestamp":1698307366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-023-01579-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":7,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1579"],"URL":"https:\/\/doi.org\/10.1007\/s00108-023-01579-x","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]},"assertion":[{"value":"9 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"E.\u00a0Roeb ist als Referentin f\u00fcr AbbVie, Amgen, Intercept, Medac, Merz, Norgine und Falk Foundation t\u00e4tig und erh\u00e4lt Beraterhonorare von den Firmen Gilead, Pfizer, Repha und Takeda. S.\u00a0Nitschmann gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}